明胶酶A及其抑制剂在卵巢癌中的表达

目的：检测明胶酶A及其抑制剂在卵巢癌中的表达情况，探讨其与卵巢癌发生、发展的关系。方法：采用免疫组织化学S－P法，检测32例卵巢上皮性恶性肿瘤、21例交界性肿瘤和10例良性肿瘤组织中明胶酶A及其抑制剂（TIMP－2）蛋白的表达状况。结果：明胶酶A及其抑制剂在肿瘤细胞和间质细胞中均可见不同程度的表达。明胶酶A蛋白在卵巢癌组织中的表达率明显高于交界性或良性肿瘤组织；TIMP－2在良性肿瘤组织中表达率最低，明显低于恶性组或交界性组；明胶酶A及其抑制剂在卵巢癌肿瘤细胞中的表达与EIGO分期相关（Ⅲ/Ⅳ期高于Ⅰ/Ⅱ期）。结论：明胶酶A可能促进卵巢癌的发生发展；内源性TIMP－2对卵巢癌的进展可能也有促进作用。

The Expression of Gelatinase A and TIMP-2 in Human Ovarian Carcinoma

Objective: To investigate the expression of gelatinase A and its inhibitor(TIMP 2) in benign,borderline and invasive epithelial ovarian tumors. Methods: 32 ovarian carcinoma, 21 borderline and 10 benign ovarian tumors were examined for the presence of MMP 2 and TIMP 2 by using the immunohistochemical method (sp method). Results: MMP 2 and TIMP 2 proteins were expressed in tumor cells as well as in stromal cells. MMP 2 expression in tumor cells or in stromal cells was found to be significantly enhanced in ovarian carcinomas compared with benign and borderline tumors. TIMP 2 expression in tumor cells or in stromal cells was found to be significantly enhanced in ovarian carcinomas or borderline tumors compared with benign tumors. There was a significantly relation between the expression of MMP 2, TIMP 2 and FIGO stage (both P<0.05) and their expression had no correlation with age of the patients and histological grade. Conclusion: MMP 2 protein appears to be a strong biologic marker for predicting the progress of ovarian carcinoma. TIMP 2 protein may play a paradoxical role in ovarian tumor progress.